Expansion of primitive hematopoietic progenitor cells (HPC) is
Introduction
The establishment of defined in vitro culture systems for hematopoietic stem/progenitor cells is a prerequisite to investigate the regulatory mechanisms of cell proliferation and diffentiation and to generate sufficient numbers of hematopoietic cells for investigational and clinical use. Early acting hematopoietic growth factors (GF) are essential for stem/progenitor cell proliferation. However, this always seems to be associated with differentiation and loss of stem cell potential. [1] [2] [3] In vivo, stem cells are found in close association with distinct cellular microenvironments. This suggests the existence of stem cell niches and implicates the importance of cell-cell contact and short-range interactions as stem cell regulatory mechanisms. 2, 4, 5 Whether the presence of bone marrow stromal cells during in vitro expansion of hematopoietic progenitor cells (HPC) is of advantage regarding loss of differentiation potential is still a matter of discussion. [6] [7] [8] There is growing evidence that cytokines bound to stromal cell surfaces or extracellular matrix (ECM) components and ECM proteins themselves are involved in regulating the balance between proliferation and differentiation. 9, 10 Cytokines known to be involved in early hematopoiesis include Flt3 ligand (FL), kit ligand (KL, SCF), thrombopoietin (TPO) and interleukin-6 (IL-6). [11] [12] [13] [14] In contrast to TPO which exerts relevant proliferative effects on its own, FL, SCF and IL-6 synergize with various other GF to stimulate proliferation and maintenance of primitive HPC in vitro. [13] [14] [15] [16] IL-6 is a member of the cytokine family which mediates its biological effects through receptor complexes that share the common subunit glycoprotein 130 (gp130). Binding of IL-6 to membranebound or soluble IL-6 receptor (sIL-6R) induces homodimerization of gp130 which leads to activation of intracellular signaling pathways. 17 Pluripotent hematopoietic progenitor cells which regularly lack IL-6R expression can be stimulated by a complex of IL-6 and sIL-6R. 17, 18 The IL-6/sIL-6R fusion protein hyper-IL-6 (H-IL-6) activates gp130 + cells at 100 to 1000-fold lower concentration than the combination of IL-6 and sIL-6R. 19 IL-6/sIL-6R fusion proteins effectively enhanced expansion of human hematopoietic progenitor cells in combination with SCF and interleukin-3 or FL and TPO in suspension culture. 20, 21 We have recently shown that H-IL-6 in combination with FL maintains primitive HPC for up to 21 days only when CD34 + cells were cocultured with murine stromal cells.
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Based on this observation, we generated murine stromal cells producing the growth factors H-IL-6 and FL which are known to stimulate early hematopoiesis. These stromal layers were tested for their ability to support expansion of committed and primitive human HPC without addition of exogenous cytokines. Furthermore, we investigated whether direct stromal cell-progenitor cell contact was required for HPC expansion. We demonstrate here that continuous presentation of early acting GF to hematopoietic cells in context with direct stromal cell contact is a useful approach for in vitro stem/progenitor cell expansion.
Materials and methods

Cells
After informed consent, cord blood (CB) cells were obtained from the umbilical cord of full-term newborns. Mononuclear cells were isolated by Ficoll density centrifugation (Seromed, Berlin, Germany) and subsequent lysis of erythrocytes. CD34 + cells were positively selected using immunomagnetic beads (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of isolated CD34 + cells was evaluated by flow cytometry (EPICS XL; Coulter, Hialeah, FL, USA) and ranged between 85% and 98%.
Antibodies
Phycoerthrin (PE)-conjugated purified mouse anti-human CD34, CD45 and matching IgG1 isotype control antibodies were pur-chased from Coulter-Immunotech (Coulter-Immunotech Diagnostics, Marseille, France). Fluorescein isothiocyanate (FITC)-conjugated purified mouse anti-human CD34, CD45 and matching isotype IgG1 control antibodies were also obtained from Immunotech.
Immunophenotyping
Two-color immunophenotyping was performed on an EPICS XL analyzer. Directly conjugated MoAbs were used to stain hematopoietic cells. Cells were stained for 30 min at 4°C followed by two washes with ice-cold PBS/0.1% NaN 3 /1% BSA and fixation with 1% formaldehyde. Determinations of background staining using matching isotype control MoAbs at the appropriate concentrations were performed in parallel in every experiment. A minimum of 10 000 events was acquired for each sample analyzed.
Cloning and transfection protocol
The cDNAs encoding H-IL-6 (S Rose-John) and the soluble form of FL (gift of Immunex, Seattle, WA, USA) were cloned into the pCDNA3.1/Neo and the pCDNA3.1/Zeo(+) vectors (Invitrogen, Carlsbad, CA, USA) using standard cloning procedures (Rapid DNA Ligation Kit; Boehringer, Mannheim, Germany; DH5␣ cells; Gibco Life Technologies, Eggenstein, Germany). Plasmids were sequenced before transfection (MWG Biotech, Ebersberg, Germany). Transfection into early passages of MS-5 cells 23 was performed using DOTAP Liposomal Transduction Reagent (Boehringer). Briefly, 2 × 10 5 MS-5 stromal cells were plated in a 10-cm diameter culture plate (Nunc, Wiesbaden, Germany) and cultured overnight. Twenty-four hours after addition of DOTAP/cDNA solution the culture medium was replaced by selection medium. After 10-14 days single clones were picked. Transfection efficiency was always below five clones per plate. Stable transfected clones were selected with 0.6 mg/ml G418 and 0.3 mg/ml Zeocin (Invitrogen).
RT-PCR
Stromal cell total RNA was obtained 72 h after the last passaging using TRIReagent (MRC, Cincinatti, OH, USA). DNA was obtained by reverse transcription reaction (Superscript RNaseH; Gibco). All reactions were performed using a Primus Thermocycler (MWG Biotech). A final extension at 72°C for 7 minutes was performed after the last cycle. The following primers (MWG Biotech) and temperatures were used (numbers of cycles/denaturation/annealing/extension). mu␤-Actin: sense 5Ј-CTAGACTTCGAGCAGGAGAT-3Ј, antisense 5Ј-GCTCAGTAACAGTCCGCCTAGA-3Ј (25/94°C; 1 min/ 58°C; 2 min/72°C; 2 min). huIL-6: sense 5Ј-AAATTCGGTACA TCCTCGAC-3Ј, antisense 5Ј-CAGGAACTGGATCAGGACTT-3Ј (30/94°C; 1 min/55°C; 2 min/72°C; 1 min). huIL-6 receptor: sense 5Ј-GAGGGAGACAGCTCTTTCTAC-3Ј, antisense 5Ј-CCGTTCAGCCCGATATCTGAG-3Ј (30/94°C; 1 min/62°C; 1 min/72°C; 1 min). huFL: sense 5Ј-CCGGCCGAAATGACAGT GCT-3Ј, antisense 5Ј-GCATCTTGGACCCAGCGACAG-3Ј (30/95°C; 1 min 20/62°C; 1 min 20/72°C; 2 min). 
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Clonal colony assays
Freshly isolated human CD34
+ cells and cells cultured in vitro for 14 to 21 days were plated in 1 ml methylcellulose containing 30% fetal bovine serum (FBS), 1% bovine serum albumin (BSA), 10 Ϫ4 M 2-mercaptoethanol, 2 mM L-glutamine and human cytokines (H4435; Stem Cell Technologies, Vancouver, Canada) in 35 mm 2 dishes (Greiner) in duplicate and incubated at 37°C, 5% CO 2 . After 14 days plates were scored for the presence of erythroid (BFU-E), granulo-monocytic (CFU-GM) and CFU-Mix by standard morphological criteria using an inverted microscope.
Cobblestone area-forming cell assay
Freshly isolated human CD34
+ cells and cells cultured in vitro were seeded on to murine FBMD1 stromal cells and cultured in DMEM containing 10% FBS, 5% horse serum, 10 mM Hepes, non-essential amino acids, 10 −4 M 2-mercaptoethanol, 1 mM sodium pyruvate, 2 mM L-glutamine in the presence of G-CSF 20 ng/ml and IL-3 10 ng/ml. Cultures were initiated in limiting dilution (eight replicate wells per dilution, 12 dilution steps) in flat-bottom 96-well plates (Corning Costar, Acton, MA, USA). After 6 weeks of incubation with weekly halfmedium changes, the percentage of wells with at least one phase-dark cobblestone area consisting of at least five cells seeding within the stromal layer was determined using an inverted microscope. The absolute number of CAFC was then calculated using Poisson statistics.
Stroma-contact and non-contact cultures
CD34
+ CB cells were seeded on to irradiated MS-5-derived stromal cells previously grown to confluence in 24-well cul-ture tissue plates in 50% Iscove's medium (Biochrom) containing 10% fetal calf serum (Biochrom) and 100 U/ml penicillin/streptomycin and 50% Myelocult 5100 medium (Stem Cell Technologies). Human growth factors were added at the following concentrations: H-IL-6 10 ng/ml, FL 100 ng/ml (R(D Systems). At various timepoints the non-adherent and adherent cell fractions were harvested. Non-adherent cells were detached by gentle pipetting. Adherent hematopoietic cells were detached by treatment with trypsin/EDTA. Adherent cells were washed once, resuspended in medium, replated in 10-cm culture plates (Falcon, Franklin Lakes, NJ, USA) and incubated at 37°C to allow reattachment of stromal cells. After 2 h, hematopoietic cells were removed by gentle pipetting. Contamination by stromal cells was evaluated using flow cytometry with staining for CD45 expression with only few stromal cells detectable. Non-contact stromal cell cocultures were performed using culture plate inserts (Millipore, Bedford, MA, USA) with 0.4 m pore size.
Statistical analysis
Statistical analysis was performed using the GraphPad Prism and Excel software programs. Data are presented as mean Ϯ standard error of the mean (s.e.m.). Analysis of statistical significance was performed using a two-tailed t-test for paired observations.
Results and discussion
Expression of hematopoietic GF in stromal cell lines is an attempt to mimic the bone marrow microenvironment of the living animal in vitro. 24 Stromal cells enable growth of HPC through production of early and late acting cytokines, membrane-bound proteins and adhesive interactions. In pilot studies, we have previously tested human and murine stromal cell lines with regard to hematopoietic support and decided to use the murine MS-5 stromal cell line. 23 MS-5 cells grow contact-inhibited and show a basic supportive capacity for human HPC. Also, human HPC adhere tightly to MS-5 cells.
7,23
Expression of Flt3 ligand and H-IL-6 in murine stromal cells
MS-5 stromal cells were cotransfected with the cDNA encoding for human FL and the cDNA encoding the IL-6/sIL-6R fusion protein H-IL-6. More than 20 clones of cotransfected MS-5 were tested for mRNA expression of human FL, IL-6 and IL-6 receptor. Expression of mRNA in clones 22, 25, 29 and 33 is shown in Figure 1 .
To quantify the production of H-IL-6 and FL in these cells, ELISA assays were performed with the supernatants. Since the H-IL-6 molecule contains epitopes of IL-6 and sIL-6R and cannot be measured directly, ELISA for IL-6 and IL-6R were performed. For IL-6, concentrations ranged from 0.1 ± 0.1 ng/ml (clone 33) up to 20.2 ± 10.5 ng/ml (clone 22) in H-IL-6/FL transfectants. sIL-6R was detected in concentration ranging from 0.4 ± 0.1 ng/ml (clone 33) to 74.7 ± 15.6 ng/ml (clone 25) (Figure 2a) . Concentrations of FL ranged from 29.8 ± 8.5 ng/ml (clone 29) to 122.0 ± 32.7 ng/ml (clone 22) (Figure 2b ). As expected, there was a rough accordance between concentrations of IL-6 and sIL-6R detected in the supernatants. The moderate disaccordance probably occurred due to irregular protease activity in independent experiments. The concentration of soluble FL detected in culture supernatants after 48 h was comparable to the concentrations in control cultures treated with exogenous recombinant human FL (100 ng/ml) once or twice a week (data not shown). In recent publications, 100 ng/ml of FL has been shown to be an optimal concentration for ex vivo stimulation of HPC in stroma-supported as well as serum-free cultures.
20,22,25,26
Murine stromal cell-derived H-IL-6 and FL are biologically active
To evaluate the biological activity of the designer cytokine H-IL-6 derived from murine stromal cells, we tested the proliferation of a GF-dependent cell line stimulated with stromal cell supernatants. We used GF-starved gp130-transfected Ba/F3 cells (Ba/F3gp130) to determine the biological activity of H-IL-6. In contrast to mock-transfected stromal cultures, diluted supernatants from H-IL-6 producing clones supported the proliferation of Ba/F3gp130 cells (Figure 3a) . Experiments with diluted supernatants from clone 22 showed proliferation of 
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Ba/F3gp130 even when dilutions up to 128-fold were used. A minimal basal stimulatory activity of supernatants from parental and mock-transfected MS-5 cells shows that these cells are not able to produce signals that efficiently stimulate cell proliferation through gp130 (Figure 3a) . Proliferation of Ba/F3gp130 with 100-to 1000-fold lower concentrations of H-IL-6 compared to the stimulation with IL-6 and sIL-6R has been shown. 19 Supernatants from murine 32D cells transfected with the cDNA encoding the receptor tyrosine kinase Flt3 were used to evaluate the biological activity of stromal cell-derived human FL. As shown in Figure 3b , FL producing MS-5 stromal cells effectively stimulate proliferation of transfected 32D cells. Mock-transfected controls showed a basal stimulatory activity comparable to murine FL (100 ng/ml, data not shown).
Coexpression of human FL and H-IL-6 by murine stromal cells supports human hematopoiesis without exogenous growth factor support
Murine MS-5 stromal cells have been shown to support human hematopoiesis. 7, 23 To obtain an efficient proliferative effect, addition of exogenous hematopoietic growth factors is mandatory. We first tested whether MS-5 single transfectants expressing H-IL-6 support hematopoiesis. In agreement with our studies using FBMD-1 stromal cells, 22 there was only a moderate increase in absolute HPC numbers with sole gp130 stimulation (data not shown). Recent studies have shown that a combination of cytokines signaling through gp130 and Flt3 or c-kit with or without further GF are suitable to expand HPC. 15, 16, [20] [21] [22] Some studies have even shown that expanded cells are able to repopulate immunodeficient mice. 20, 25 H-IL-6 has been shown to be active on IL-6R + as well as IL-6R − cells, which represent the more primitive stem/progenitor cell population, 18 and on presumably even more primitive Lin − CD34 − CD38 − cells. 25 H-IL-6 and FL producing stromal cell clones (clone 22, clone 25, clone 29 and clone 33) were tested for their capacity to stimulate the proliferation of committed and early human HPC. These clones were selected for their ability to express the transgenes/proteins and were not preselected in regard to their capacity to support human CD34 + progenitor cells. As a control, mock-transfected MS-5 cells with and without exogenous H-IL-6 (10 ng/ml) and FL (100 ng/ml) were evaluated. 3 × 10 4 CD34 + CB cells were cultured on transfected stromal cells with or without exogenous GF for up to 21 days. There was an efficient stimulation of proliferation both in FL/H-IL-6-clones and GF-supported mock transfectants compared to medium-supported mock transfectants. GM/Mix on day 14 and 11.7-fold CFU-GM/Mix on day 21 (clone 22). Clone 25 generated an increase of 5.0-and 7.3-fold, clone 29 of 7.3-and 7.9-fold and clone 33 of 4.0-and 4.9-fold on day 14 and day 21 compared to input CFU-GM/Mix (Figure 4b ). To evaluate whether only mature progenitor cells or also early progenitor cells were expanded, we tested CAFC week6 activity after 14 and 21 days of coculture (Figure 4c) . In control cultures without GF, there was a moderate decrease of CAFC activity with 0.9-fold on day 14 and 0.7-fold compared to day 0. Control cultures supported with exogenous H-IL-6 and FL caused a 2.3-fold (day 14) and 1.5-fold (day 21) increase in absolute CAFC number compared to day 0. The best expansion of CAFC on day 14 and day 21 was seen in coculture with clone 22, which caused a 6.5-fold and a 6.2-fold increase on day 14 and day 21. The three other H-IL-6/FL producing transfectants tested also stimulated CAFC growth comparable to controls supported with exogenous GF (Figure 4c) . Figure 4a -c demonstrates that the engineered feeder layers supported the proliferation of committed HPC measured as CFC and early HPC measured as week6 CAFC without exogenous GF support. All tested clones expanded early progenitor cells at least as well as control cultures (mock transfectants supported with FL 100 ng/ml and H-IL-6 10 ng/ml as previously tested optimal concentrations). Expansion of CFC and CAFC in coculture with clone 22 reached statistical significance (P Ͻ 0.05). In all experiments the adherent and non-adherent cell fractions were evaluated seperately for progenitor cell content. Table 1 shows the percentage of cells, CFU-GM/Mix and CAFC in the adherent cell layer. Under all conditions, there was a correlation between the percentage of adherent cells and adherent committed and primitive progenitors.
Other groups have shown higher expansion rates for committed and early HPC in suspension and stromal-based culture systems, but these experiments used exogenous GF and hematopoietic cells employed were mostly selected for lin
− or thy-1 + cells which represent more primitive starting HPC populations. 7, 13, 20, [25] [26] [27] In order to demonstrate that the combination of Flt3 and gp130 activation is mandatory to stimulate the proliferation of CD34 + cells in our system, experiments with single transfectants (H-IL-6) or single exogenous H-IL-6 or FL stimulation were performed. These experiments did not show relevant expansion (H-IL-6) or significantly lower proliferation of early HPC (FL), suggesting that one of these factors in combination with basal murine stromal activity is not suitable for progenitor cell expansion (data not shown). Delayed addition (day 7 vs day 0) of H-IL-6 to a cytokine cocktail containing FL and SCF causes a significant decrease in proliferation of HPC. 22 This suggests that IL-6 in the case of IL-6R + cells and H-IL-6 in the case of more primitive IL-6R − cells are GF suitable for continuous presentation in a stromal cell coculture system. Considering the data from ELISA (Figure 2) , proliferation experiments ( Figure 3 ) and the expansion experiments shown in Figure 4a -c, we conclude that production of sufficient concentrations of bioactive H-IL-6 in combination with a high concentration of bioactive human FL is effective to maintain and expand human primitive progenitor cells. These conditions are ideally provided by the MS-5-derived stromal cell clone 22 without addition of exogenous GFs. Hyper-IL-6 has been shown to be a potent activator of STAT3-dependent gene transcription in murine cells in vivo and in vitro 28 and to alter the expression of adhesion molecules like VCAM-1. 29 Therefore, we cannot rule out that the expression of H-IL-6 in murine stromal cells affects cocultured human hematopoietic cells indirectly.
Stromal cell-progenitor cell contact is necessary to maintain early hematopoietic progenitor cells
Next, we wished to determine whether direct cellular interaction between murine stromal cells and human HPC is necessary to maintain primitive HPC activity or whether production 
CD34
+ CB cells were cultured in direct contact with mock transfected MS-5 with medium alone (mock med) or supported with exogenous H-IL-6 10 ng/ml and FL 100 ng/ml (mock GF) or on H-IL-6/FL producing stromal cells (22, 25, 29 and 33) . After 14 and 21 days the percentage of human hematopoietic cells, CFU-GM/Mix and week 6 CAFC in the adherent and nonadherent cell fraction were evaluated separately. Numbers give the percentage Ϯ SEM of adherent cells, CFU-GM/Mix and CAFC refered to the total culture output.
of soluble GF by stromal cells is sufficient for HPC maintenance. For this purpose, CD34
+ CB cells were cultured in direct stromal contact with the above described transfectants or separated by culture plate inserts from H-IL-6/FL producing stromal cells. The absolute cell number, representing cell proliferation after 14 days of in vitro culture, was unaffected by inhibiton of direct progenitor cell-stromal cell contact ( Figure  5, upper left panel) . However, the number of CFU-GM/Mix in non-contact cultures was reduced to about 73% of contact CFU-GM/Mix ( Figure 5 , upper right panel). Differences were pronounced and reached statistical significance when BFUe numbers (33%) and CAFC numbers (24%) of non-contact and contact cultures were compared ( Figure 5 , lower left and right panel). In control cultures without GF support no CAFC and BFU-e activity was detected after 14 days when contact was prohibited (data not shown). Similar results have been observed in other culture systems with only 15% LTC-IC activity obtained after a 5 week culture period when contact was inhibited. 30 For SCF, it has been demonstrated that selec-
Figure 5
Inhibition of direct progenitor cell-stromal cell contact results in decreased early HPC numbers while absolute cell proliferation remains unaffected. 3 × 10 4 human CD34 + cells freshly isolated from cord blood were cultured on H-IL-6/FL producing stromal cells in direct contact (contact) or separated by culture plate inserts (noncontact). After 14 days, absolute cell number (cell number) was measured and cells were further evaluated for committed HPC (CFU-GM, BFUe) and early HPC (week6 CAFC) activity. Data are presented as the total mean Ϯ s.e.m. of three independent experiments each performed with clones 22, 25, 29 and 33.
Leukemia tive presentation of membrane-bound vs soluble isoforms affects stimulation of HPC. 31 It remains speculative whether local presentation of GF (eg FL and H-IL-6, murine SCF), higher local concentration of cytokines in contact cultures or cell-cell communication through adhesion molecules or ECM proteins preserves differentiation potential. Most hematopoietic cells from the experiments shown in Figure 4b and c were found in the adherent cell fraction (Table 1) . Interestingly, the frequency of committed and primitive HPC was nearly the same in the adherent and nonadherent cell fraction and corresponded well to the proportion of adherent and nonadherent cells (Table 1) . Considering the results shown in Figure 5 , this leads to the conclusion that primitive HPC at least intermittently need contact to stromal cells or ECM proteins to maintain differentiation potential while continuous adherence may be dispensable.
In this report, we show the generation of a murine stromal feeder layer that continuously provides early acting growth factors to cocultured hematopoietic progenitor cells. These progenitor cells can be maintained and expanded without addition of exogenous cytokines. Prohibition of direct stromal cell-progenitor cell contact significantly decreased proliferation of early hematopoietic progenitor cells even though overall proliferation was preserved. Presentation of growth factors in stromal cell contact cultures seems to be a useful strategy to gain progenitor cells for investigational and clinical use.
